Surgical oncology · 2025
ERAS pathway adherence and its association with return to intended oncological therapy after gastrectomy.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bretscher Ana León, Melchor Javier Ripollés, Nebreda María García, Motos Ane Abad, Morales Carla Iglesias, Tena Guerrero José María, Lapetra Cristina Gil, Orts Micó Francisco José, Pérez Manuel Llácer, Menéndez Patricia Galán, Alday-Muñoz Enrique, Domínguez Jorge Puertas, Sierra Bakarne Ugarte, Bellosta Ana Maria Pascual, Navarro-Perez Rosalia, Risco Raquel, Blanco Virginia Moreno, Álvarez Raquel García, Zamora Irene Mojarro, Gurumeta Alfredo Abad, Crespo Gloria Paseiro
Аннотация
BACKGROUND: Enhanced Recovery After Surgery (ERAS) pathways improve short-term outcomes in abdominal surgery, but their impact on timely initiation of adjuvant chemotherapy (Return to Intended Oncologic Therapy, RIOT) in gastric cancer remains uncertain.
METHODS: This multicenter, prospective cohort study (POWER4, NCT03865810) analysed 742 patients undergoing gastrectomy across 72 Spanish hospitals (2019-2020). ERAS adherence was assessed by quartiles.
PRIMARY OUTCOME: timely RIOT (chemotherapy initiation ≤56 days post-surgery).
SECONDARY OUTCOME: time to RIOT (days). Multivariable logistic and Cox regression models adjusted for clinical/tumour factors.
RESULTS: Of 742 patients, 65 % achieved timely RIOT. Quartile-based univariable analysis revealed shorter time to RIOT with higher adherence (Q4 vs. Q1: HR 0.64, 95 % CI 0.42-0.97, *p* = 0.034), but this association disappeared in multivariable models. Advanced TNM stage (e.g.
, IIIC: HR 18.6, *p* < 0.001) and ASA class were stronger predictors of delayed RIOT.
CONCLUSIONS: While ERAS pathways may aid recovery, their impact on RIOT depends on high adherence and is overshadowed by tumour-related factors. Future efforts should integrate ERAS with prehabilitation for high-risk patients and target adherence thresholds ≥70 %.
METHODS: This multicenter, prospective cohort study (POWER4, NCT03865810) analysed 742 patients undergoing gastrectomy across 72 Spanish hospitals (2019-2020). ERAS adherence was assessed by quartiles.
PRIMARY OUTCOME: timely RIOT (chemotherapy initiation ≤56 days post-surgery).
SECONDARY OUTCOME: time to RIOT (days). Multivariable logistic and Cox regression models adjusted for clinical/tumour factors.
RESULTS: Of 742 patients, 65 % achieved timely RIOT. Quartile-based univariable analysis revealed shorter time to RIOT with higher adherence (Q4 vs. Q1: HR 0.64, 95 % CI 0.42-0.97, *p* = 0.034), but this association disappeared in multivariable models. Advanced TNM stage (e.g.
, IIIC: HR 18.6, *p* < 0.001) and ASA class were stronger predictors of delayed RIOT.
CONCLUSIONS: While ERAS pathways may aid recovery, their impact on RIOT depends on high adherence and is overshadowed by tumour-related factors. Future efforts should integrate ERAS with prehabilitation for high-risk patients and target adherence thresholds ≥70 %.